Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Rgenta Therapeutics Inc
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06462183CT.gov Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenoid Cystic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rgt-61159 (this asset) | Rgenta Therapeutics Inc | P1 | CC · 43 |
| Cetuximab | Fox Chase Cancer Center | P1/2 | B |
| Irinotecan | National Cancer Institute (NCI) | P1/2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Vipivotide Tetraxetan | Maria Sklodowska-Curie National Research Institute of Oncology | P2 | CCC |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | CCC |
| Everolimus | Emory University | P1 | CCC |
| Pembrolizumab | Seagen, a wholly owned subsidiary of Pfizer | P1/2 | CCC |
| Alvespimycin | National Cancer Institute (NCI) | P1 | CC |
+20 more in the Adenoid Cystic Carcinoma cohort
Other indications for Rgt-61159
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rgt-61159 in Adenoid Cystic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rgt-61159-adenoid-cystic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →